Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Montelukast. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 known ✓ | Q9Y271 | 15/20 | 1.00 |
| ▸ | CYSLTR2 | Q9NS75 | 14/20 | 1.00 |
| ▸ | CYP2C8 | P10632 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | RECQL | P46063 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 1/20 | 1.00 |
| ▸ | FYN | P06241 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 1/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Montelukast SCHEMBL29369663 | 1.00 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| Montelukast SCHEMBL4487 | 1.00 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| Montelukast SCHEMBL31060351 | 1.00 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| Montelukast SCHEMBL15656168 | 1.00 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| Montelukast SCHEMBL1149660 | 1.00 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| Montelukast SCHEMBL4486 | 1.00 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| Montelukast SCHEMBL12702747 | 1.00 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| Montelukast SCHEMBL22207045 | 1.00 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| Montelukast SCHEMBL21635556 | 1.00 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| Montelukast SCHEMBL29674830 | 1.00 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150087690-A1 | G PROTEIN-COUPLED PURINERGIC RECEPTOR Gpr17 MEDIATES OREXIGENIC EFFECTS OF FOXO1 IN AGRP NEURONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-03-26 | — | — | US | claimed |
| EP-1933842-A2 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | Amira Pharmaceuticals, Inc. (US) | 2008-06-25 | — | — | EP | claimed |
| WO-2007047207-A2 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-04-26 | — | — | WO | claimed |
| CN-117024340-A | Synthesis method of montelukast sodium | 迪嘉药业集团股份有限公司 | 2023-11-10 | — | — | CN | disclosed |
| WO-2020245358-A1 | MONTELUKAST SALTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | GENETIC S.P.A. (IT) | 2020-12-10 | — | — | WO | disclosed |
| US-10758478-B2 | Active agent loaded uniform, rigid, spherical, nanoporous calcium phosphate particles and methods of making and using the same | LABORATORY SKIN CARE, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| EP-3505172-A1 | A PHARMACEUTICAL COMPOSITION COMPRISING MONTELUKAST AND LEVOCETIRIZINE | Abdi Ibrahim Ilac Sanayi ve Ticaret A.S. (TR) | 2019-07-03 | — | — | EP | disclosed |
| US-9717684-B2 | Stable montelukast solution | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2017-08-01 | — | — | US | disclosed |
| US-9616056-B2 | Inhibition of leukotriene synthesis and activity in the treatment of sonic hedgehog-associated medulloblastoma | INSTITUTE FOR CANCER RESEARCH (US) | 2017-04-11 | — | — | US | disclosed |
| EP-3134076-A1 | A STABLE MONTELUKAST SOLUTION | R.P. Scherer Technologies, LLC (US) | 2017-03-01 | — | — | EP | disclosed |
| US-9359376-B2 | Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds | SPHAERA PHARMA PTE. LTD (SG) | 2016-06-07 | — | — | US | disclosed |
| WO-2005065649-A1 | INHALANT FORMULATION CONTAINING SULFOALKYL ETHER Ϝ-CYCLODEXTRIN AND CORTICOSTEROID | CYDEX, INC. (US) | 2005-07-21 | — | — | WO | disclosed |
| EP-1357928-A4 | A NOVEL PHARMACEUTICAL COMPOUND AND METHODS OF MAKING AND USING SAME | NEW RIVER PHARMACEUTICALS INC (US) | 2004-12-29 | — | — | EP | disclosed |
| EP-1490090-A2 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | New River Pharmaceuticals Inc. (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2004043966-A1 | NEW TRICYCLIC DERIVATIVES AS LTD4 ANTAGONISTS | ALMIRALL PRODESFARMA S.A. (ES) | 2004-05-27 | — | — | WO | disclosed |
| WO-2003066598-A9 | NOVEL ANHYDROUS AMORPHOUS FORMS OF MONTELUKAST SODIUM SALT | REDDYS LAB LTD DR (IN) | 2003-12-04 | — | — | WO | disclosed |
| EP-1357928-A2 | A NOVEL PHARMACEUTICAL COMPOUND AND METHODS OF MAKING AND USING SAME | New River Pharmaceuticals Inc. (US) | 2003-11-05 | — | — | EP | disclosed |
| WO-2003079972-A2 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | NEW RIVER PARMACEUTICALS INC. (US) | 2003-10-02 | — | — | WO | disclosed |
| WO-2003066598-A1 | NOVEL ANHYDROUS AMORPHOUS FORMS OF MONTELUKAST SODIUM SALT | DR. REDDY'S LABORATORIES LTD. (IN) | 2003-08-14 | — | — | WO | disclosed |
| WO-2003020200-A2 | A NOVEL PHARMACEUTICAL COMPOUND AND METHODS OF MAKING AND USING SAME | NEW RIVER PHARMACEUTICALS INC. (US) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10758478-B2 | Active agent loaded uniform, rigid, spherical, nanoporous calcium phosphate particles and methods of making and using the same | CHERP, ORAI1, CA2 | CYSLTR1 2990/4885CYSLTR2 2852/4885CYP2C8 4474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.